AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 6.28 |
Market Cap | 655.49M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.91 |
PE Ratio (ttm) | -17.18 |
Forward PE | n/a |
Analyst | Buy |
Ask | 25 |
Volume | 386,065 |
Avg. Volume (20D) | 362,275 |
Open | 16.32 |
Previous Close | 16.23 |
Day's Range | 14.83 - 16.34 |
52-Week Range | 11.70 - 21.64 |
Beta | undefined |
About SIBN
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section...
Analyst Forecast
According to 6 analyst ratings, the average rating for SIBN stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 40.75% from the latest price.
Next Earnings Release
Analysts project revenue of $46.89M, reflecting a 20.67% YoY growth and earnings per share of -0.14, making a -48.15% decrease YoY.